FDA Policy/General

Latest Federal Register Notices

FDA Withdraws 3 Sun Pharma ANDAs
Federal Register notice: FDA withdraws three Sun Pharmaceutical Industries ANDAs because they are no longer marketed. 05/04/2018

9 No Longer Marketed ANDAs Withdrawn
Federal Register notice: FDA withdraws the approval of nine ANDAs from multiple applicants. 05/04/2018

Needle Destruction Device Down Classified
Federal Register notice: FDA issues a final order to reclassify the needle destruction device into Class 2 (special controls)and subject to premarket notification. 05/04/2018

Guide on PDUFA Implementation
Federal Register notice: FDA makes available a final guidance entitled “Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017.” 05/03/2018

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome